<div><div></div><div>Cellectar Biosciences entered multiple agreements to complete a capital raise of approximately $35 million through a registered direct offering and concurrent private placement. The financing includes common stock, pre-funded warrants, and milestone-based Tranche A, B, and C warrants, with proceeds earmarked for working capital and the planned Phase 3 trial of iopofosine I 131 in Waldenström macroglobulinemia. The company also granted resale registration rights to investors, engaged Ladenburg Thalmann as placement agent with standard fees and warrants, and agreed to appoint an independent director designated by Nantahala Capital Management. The offering closed on May 6, 2026.Agreement 1: Cellectar Biosciences Raises ~$35 Million in Registered Direct and Private Placement<ul><li>Agreement type: Securities purchase agreement for registered direct offering and concurrent private placement</li><li>Counterparty: Certain Institutional Investors</li><li>Signed / Effective: May 04 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Raise capital for working capital and Phase 3 WM trial</li></ul>Agreement 2: Cellectar Biosciences Adds Management Participation in Private Placement at $2.88 Per Share<ul><li>Agreement type: Securities purchase agreement for management participation in private placement</li><li>Counterparty: Executive Management Participants</li><li>Signed / Effective: May 04 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Align management interests and support capital raise</li></ul>Agreement 3: Cellectar Biosciences Grants Investors Resale Registration Rights for Offering Securities<ul><li>Agreement type: Registration rights agreement for resale of shares and warrant shares</li><li>Counterparty: Certain Investors</li><li>Signed / Effective: May 04 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Provide resale liquidity to investors</li></ul>Agreement 4: Cellectar Biosciences Engages Ladenburg Thalmann as Placement Agent for $35 Million Offering<ul><li>Agreement type: Placement agency agreement for equity offering</li><li>Counterparty: Ladenburg Thalmann</li><li>Signed / Effective: May 04 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Execute and distribute the capital raise</li></ul>Agreement 5: Cellectar Biosciences to Add Nantahala-Designated Independent Director Under Side Letter<ul><li>Agreement type: Board designation side letter</li><li>Counterparty: Nantahala Capital Management</li><li>Signed / Effective: May 04 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Enhance governance alignment with investors</li></ul>Original SEC Filing: Cellectar Biosciences, Inc. [ CLRB ] - 8-K - May. 08, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

CLRB

ARKG

LABU

SBIO

Cellectar Biosciences has raised approximately $35 million through a registered direct offering and private placement. The financing includes common stock, pre-funded warrants, and milestone-based warrants, aimed at funding working capital and a Phase 3 trial for iopofosine I 131 in Waldenström macroglobulinemia. The company has granted resale registration rights to investors and appointed an independent director designated by Nantahala Capital Management. The offering closed on May 6, 2026.

TradingView

Cellectar Bioscience

Ark Genomic Revolution ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Cellectar Biosciences Raises ~$35 Million in Registered Direct and Private Placement